CVS Health Adds Yeztugo HIV Prevention Drug to Insurance Plans
CVS Health has added Gilead Sciences' Yeztugo to its commercial insurance plans, effective January 1, 2026. This move reverses a prior decision and boosts the drug's coverage to over 80%, enhancing its market penetration.
Insights:
CVS Health Corporation has officially included Gilead Sciences Inc.'s groundbreaking HIV prevention drug, Yeztugo, in its commercial insurance plans as of January 1, 2026. This decision marks a significant reversal from CVS's previous stance in August 2025 when it excluded the drug based on clinical, financial, and regulatory considerations. The inclusion of Yeztugo now raises its total insurer coverage to over 80%, underscoring its growing acceptance in the market.
